Exercise or conversion by Noyes Timothy P of 15000 shares of Aerovate Therapeutics subject to Rule 16b-3

AVTE Stock  USD 2.56  0.03  1.19%   
About 54% of Aerovate Therapeutics' shareholders are presently thinking to get in. The analysis of the overall investor sentiment regarding Aerovate Therapeutics suggests that some traders are interested. The current market sentiment, together with Aerovate Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Aerovate Therapeutics stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Aerovate Therapeutics Inc director. Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Read at macroaxis.com
Aerovate insider trading alert for exercise of common stock by Noyes Timothy P, CHIEF EXECUTIVE OFFICER, on 3rd of May 2023. This event was filed by Aerovate Therapeutics Inc with SEC on 2023-05-03. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

Aerovate Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Aerovate Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

Aerovate Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Aerovate Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Aerovate Therapeutics Fundamental Analysis

We analyze Aerovate Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aerovate Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aerovate Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Net Income

Net Income Comparative Analysis

Aerovate Therapeutics is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Aerovate Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Aerovate Therapeutics stock to make a market-neutral strategy. Peer analysis of Aerovate Therapeutics could also be used in its relative valuation, which is a method of valuing Aerovate Therapeutics by comparing valuation metrics with similar companies.

Complementary Tools for Aerovate Stock analysis

When running Aerovate Therapeutics' price analysis, check to measure Aerovate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aerovate Therapeutics is operating at the current time. Most of Aerovate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aerovate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aerovate Therapeutics' price. Additionally, you may evaluate how the addition of Aerovate Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals